Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease

Renato X. Santos; Sonia C. Correia; Susana Cardoso; Cristina Carvalho; Maria S. Santos; Paula I. Moreira

doi:10.1111/j.1471-4159.2011.07262.x

Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease

Renato X. Santos, Sonia C. Correia, Susana Cardoso, Cristina Carvalho, Maria S. Santos, Paula I. Moreira^*

^*Corresponding author for this work

University of Coimbra

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

Rapamycin is a macrolide immunosuppressant drug, originally used as an anti‐fungal agent, which is widely used in transplantation medicine to prevent organ rejection. Target of rapamycin (TOR) is an evolutionarily conserved serine/threonine kinase with pleiotropic cellular functions, regulating processes such as growth and metabolism, cell survival, transcription and autophagy. TOR intervenes in two distinct enzymatic complexes with different functions, a rapamycin‐sensitive complex TORC1 and a rapamycin‐insensitive complex TORC2. Rapamycin has an inhibitory effect on TORC1 activity and it has been suggested to increase life span, an effect correlated with decreased protein biosynthesis and autophagy activation. In the CNS, rapamycin shows beneficial effects in neuronal survival and plasticity, thus contributing to memory improvement. In this review, evidence implying rapamycin and TOR in aging/life span extension and memory improvement will be discussed. Recent findings about the effects of rapamycin on Alzheimer’s disease‐associated neuropathology will be also discussed.

Original language	English
Pages (from-to)	927-936
Number of pages	10
Journal	Journal of Neurochemistry
Volume	117
Issue number	6
Early online date	3 May 2011
DOIs	https://doi.org/10.1111/j.1471-4159.2011.07262.x
Publication status	Published - Jun 2011
Externally published	Yes

Bibliographical note

Acknowledgements
Renato X. Santos has a PhD fellowship from the Fundação para a Ciência e a Tecnologia (SFRH/BD/43972/2008). Work in the authors’ laboratories is supported by Fundação para a Ciência e a Tecnologia (PTDC/SAU‐NEU/103325/2008 and PTDC/SAU‐NMC/110990/2009).

Keywords

agin
Alzheimer's disease
memory
rapamycin
TOR

Access to Document

10.1111/j.1471-4159.2011.07262.xLicence: Unspecified

Cite this

@article{b7c16e79189c41b899d30f5a902a7972,

title = "Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease",

abstract = "Rapamycin is a macrolide immunosuppressant drug, originally used as an anti‐fungal agent, which is widely used in transplantation medicine to prevent organ rejection. Target of rapamycin (TOR) is an evolutionarily conserved serine/threonine kinase with pleiotropic cellular functions, regulating processes such as growth and metabolism, cell survival, transcription and autophagy. TOR intervenes in two distinct enzymatic complexes with different functions, a rapamycin‐sensitive complex TORC1 and a rapamycin‐insensitive complex TORC2. Rapamycin has an inhibitory effect on TORC1 activity and it has been suggested to increase life span, an effect correlated with decreased protein biosynthesis and autophagy activation. In the CNS, rapamycin shows beneficial effects in neuronal survival and plasticity, thus contributing to memory improvement. In this review, evidence implying rapamycin and TOR in aging/life span extension and memory improvement will be discussed. Recent findings about the effects of rapamycin on Alzheimer{\textquoteright}s disease‐associated neuropathology will be also discussed.",

keywords = "agin, Alzheimer's disease, memory, rapamycin, TOR",

author = "Santos, {Renato X.} and Correia, {Sonia C.} and Susana Cardoso and Cristina Carvalho and Santos, {Maria S.} and Moreira, {Paula I.}",

note = "Acknowledgements Renato X. Santos has a PhD fellowship from the Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia (SFRH/BD/43972/2008). Work in the authors{\textquoteright} laboratories is supported by Funda{\c c}{\~a}o para a Ci{\^e}ncia e a Tecnologia (PTDC/SAU‐NEU/103325/2008 and PTDC/SAU‐NMC/110990/2009).",

year = "2011",

month = jun,

doi = "10.1111/j.1471-4159.2011.07262.x",

language = "English",

volume = "117",

pages = "927--936",

journal = "Journal of Neurochemistry",

issn = "0022-3042",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease

AU - Santos, Renato X.

AU - Correia, Sonia C.

AU - Cardoso, Susana

AU - Carvalho, Cristina

AU - Santos, Maria S.

AU - Moreira, Paula I.

N1 - Acknowledgements Renato X. Santos has a PhD fellowship from the Fundação para a Ciência e a Tecnologia (SFRH/BD/43972/2008). Work in the authors’ laboratories is supported by Fundação para a Ciência e a Tecnologia (PTDC/SAU‐NEU/103325/2008 and PTDC/SAU‐NMC/110990/2009).

PY - 2011/6

Y1 - 2011/6

N2 - Rapamycin is a macrolide immunosuppressant drug, originally used as an anti‐fungal agent, which is widely used in transplantation medicine to prevent organ rejection. Target of rapamycin (TOR) is an evolutionarily conserved serine/threonine kinase with pleiotropic cellular functions, regulating processes such as growth and metabolism, cell survival, transcription and autophagy. TOR intervenes in two distinct enzymatic complexes with different functions, a rapamycin‐sensitive complex TORC1 and a rapamycin‐insensitive complex TORC2. Rapamycin has an inhibitory effect on TORC1 activity and it has been suggested to increase life span, an effect correlated with decreased protein biosynthesis and autophagy activation. In the CNS, rapamycin shows beneficial effects in neuronal survival and plasticity, thus contributing to memory improvement. In this review, evidence implying rapamycin and TOR in aging/life span extension and memory improvement will be discussed. Recent findings about the effects of rapamycin on Alzheimer’s disease‐associated neuropathology will be also discussed.

AB - Rapamycin is a macrolide immunosuppressant drug, originally used as an anti‐fungal agent, which is widely used in transplantation medicine to prevent organ rejection. Target of rapamycin (TOR) is an evolutionarily conserved serine/threonine kinase with pleiotropic cellular functions, regulating processes such as growth and metabolism, cell survival, transcription and autophagy. TOR intervenes in two distinct enzymatic complexes with different functions, a rapamycin‐sensitive complex TORC1 and a rapamycin‐insensitive complex TORC2. Rapamycin has an inhibitory effect on TORC1 activity and it has been suggested to increase life span, an effect correlated with decreased protein biosynthesis and autophagy activation. In the CNS, rapamycin shows beneficial effects in neuronal survival and plasticity, thus contributing to memory improvement. In this review, evidence implying rapamycin and TOR in aging/life span extension and memory improvement will be discussed. Recent findings about the effects of rapamycin on Alzheimer’s disease‐associated neuropathology will be also discussed.

KW - agin

KW - Alzheimer's disease

KW - memory

KW - rapamycin

KW - TOR

UR - http://europepmc.org/abstract/med/21447003

U2 - 10.1111/j.1471-4159.2011.07262.x

DO - 10.1111/j.1471-4159.2011.07262.x

M3 - Article

C2 - 21447003

SN - 0022-3042

VL - 117

SP - 927

EP - 936

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

IS - 6

ER -

Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this